Assessment of clinically relevant immunogenicity for mAbs; are we over reporting ADA?
2020
Immunogenicity is recognized as a possible clinical risk due to the development of anti drug antibodies (ADAs) that can adversely impact drug safety and efficacy. Although robust assays are current...
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
48
References
2
Citations
NaN
KQI